WO2022069013A1

WO2022069013A1 - Medicinal composition for the treatment and prevention of covid-19 and other infections and conditions. novel uses of alpha-acetoxytoluene, benzyl alcohol and benzyl groups for controlling the covid-19 pandemic and other infections and conditions

Info

Publication number: WO2022069013A1
Application number: PCT/DZ2020/050011
Authority: WO
Inventors: Bencherguia OMAR
Original assignee: Omar Bencherguia
Priority date: 2020-10-04
Filing date: 2020-11-18
Publication date: 2022-04-07

Abstract

The present invention relates to a medicinal composition for the treatment and prevention of viral infections, in particular Covid-19, inflammatory and haematological pathologies. This composition comprises benzyl alcohol, benzaldehyde and/or benzoic acid or a derivative thereof.

Description

TITLE OF THE INVENTION

Medicinal composition for the treatment and prevention of covid-19 and other infections and conditions

New applications of alpha-acetoxytoluene, benzyl alcohol and benzyl groups in the fight against the covid-19 pandemic and other infections and conditions

TECHNICAL FIELD TO WHICH THE INVENTION RELATES

The present invention relates to a new therapeutic application of pharmaceutically acceptable alcoholic and/or benzyl molecules, aimed at antiviral: Benzyl alcohol as active principle represented by the formula (C ₇ H ₈ O), and its precursors or mixtures have as principle active benzyl alcohol such as: alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) an benzoic acid precursor, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid.

For this new therapeutic indication according to the invention, which is that of the treatment and prevention of the new Covid-19 pandemic and other infections by other pathogenic agents, especially viral ones, as well as other conditions such as flu, tumors, inflammatory and haematological pathologies, benzyl alcohol and its precursors or mixtures have as active ingredient benzyl alcohol such as: alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor of benzoic acid, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid are presented in a new galenic form and applied according to new routes of administration.

This invention is likely to have a large number of applications: the treatment and prevention of the current Covid-19 pandemic and subsequent epidemics or pandemics, the treatment of viral infections or other pathogenic agents such as flu, HIV, hepatitis B and C, Ebola, Zika ... as well as other tumoral, inflammatory and hematological pathologies.

Starting from the observation and analysis of the virological and immunological characteristics of SARS-CoV-2 responsible for the current pandemic, the clinical and biological manifestations of patients from the available bibliography; initially the inventor selected several molecules and chemical compounds whose antiviral power is demonstrated and understood against SARS CoV-2, then the inventor selected molecules whose human administration is possible.

Secondly and using molecular physico-chemical, toxicological and toxicokinetic knowledge as well as studies from the literature, the inventor selected the molecules that best met his selection criteria and were capable of being administered intravenously. and/or oral and has given the arguments in favor of these routes as well as the effective inhibitory doses that can be administered, the inventor explains the mechanisms of direct antiviral action on viruses and indirect by modulating the immune and cellular reactions.

The inventor shows that benzyl alcohol as an active ingredient, and its precursors or its mixtures are capable of producing viral protein denaturation, disturbances in the thickness, permeability, intrinsic conductance and polarity of the viral phospholipid membrane, also these molecules prevent the penetration of viruses inside the cells by different mechanisms.

The inventor shows that benzyl alcohol, its precursors and mixtures with benzyl alcohol as active ingredient; influence immune signaling pathways and effectively reduce cytokine levels; these molecules exert their actions without cellular or tissue damage.

The inventor also shows a large database of literature on toxicity, clinical trials on animals and humans of the active ingredient "benzyl alcohol" and alpha-acetoxytoluene where the administrable molecule as well as other precursors, derivatives and mixtures.

The inventor has highlighted the doses and routes of administration of the new application of alpha-acetoxytoluene and benzyl alcohol, its precursors, its derivatives and its mixtures, in order to allow effective antiviral and immune actions. without reaching toxic doses and without causing cell or tissue damage. The molecules therefore concerned by the present invention are: Benzyl alcohol as active principle represented by the formula (C ₇ H ₈ O), administered directly or indirectly by the administration of its precursors, its derivatives, or its mixtures have as a bioactive ingredient benzyl alcohol such as: alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor to benzoic acid, toluene, deuteriobenzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid.

The medicinal composition according to the invention is in particular in the form of serums for intravenous infusion or where oral or cutaneous dosage forms containing:

Benzyl alcohol as active principle or bioactive after metabolism and its precursors, its derivatives or its mixtures with a concentration of 0.0001 mg/ml to 6000 mg/ml for intravenous infusion except for its presence in low concentrations as a bacteriostatic preservative in drug formulations at doses of less than 20 mg/ml maximum.

Benzyl alcohol as active principle or bioactive after metabolism and its precursors, its derivatives or its mixtures with a concentration of 0.001 mg/kg/d to 6000 mg/kg/d for the oral form except for its presence at low concentrations as a preservative bacteriostatic in drug formulations at doses of less than 20 mg/ml maximum; therefore the invention also relates to:

The direct or slow intravenous route for infusions except for its presence in low concentrations as a bacteriostatic preservative in medicinal formulations at doses of less than 20 mg/ml maximum;

The parenteral route for higher daily doses of 2.15mg/kg/d except for its presence in low concentrations as a bacteriostatic preservative in medicinal formulations at doses of less than 20mg/ml maximum;

And possibly the oral route by syrups, tablets, capsules, or others.

The medicinal composition according to the invention is in particular in the oral form or of a solution or of physiological serum buffered at neutral pH or close to neutral for parenteral or oral infusion containing the active principles of benzyl alcohol or one of their precursors or a mixture:

The concentration of the active ingredient in this solution is between approximately 0.0001% and approximately 6% (w/v).

The active agent is a pharmaceutically acceptable liquid chosen in particular from volatile organic compounds and mixtures thereof.

The medicament according to the invention is intended for the treatment and prevention, in humans and animals, of Covid-19 in the initial as well as late phases as well as other pathologies in particular: other infections by other pathogens such as flu, HIV, hepatitis, Ebola, Zika, etc. benign and malignant tumours, inflammatory and hematological pathologies.

The mechanism of this therapeutic effect could also be established:

- Benzyl alcohol, due to its small size, crosses all physiological barriers; hemato-encephalic and placental, it has a better diffusion in all the tissues as well as it penetrates inside the host cells and this without causing persistent damage (the alteration of the cell receptors makes the cell insensitive to infection viral by inhibiting the penetration of the virus, either by altering the cellular receptors of the membrane or by competition phenomena); benzyl alcohol also penetrates the virus itself by passing through its phospholipid membrane by changing the conformation of this membrane leading to dissolution, disorganization and modification of the thickness and permeability and by denaturing its proteins and this allows benzyl alcohol to inactivate the virus or even destroy it.

- Benzyl alcohol exerts actions on the immune system by reducing cytokine levels and allows the activation of immune signaling pathways. This characteristic allows a kind of fight against the cytokine storm (harmful manifestation of the disease Covid-19)

- Benzyl alcohol has a mild hypotensive effect at an optimal dose.

The drug alpha-acetoxytoluene has a rapid metabolism in the bioactive molecule "benzyl alcohol", a half-life of 90 minutes, urinary elimination in the form of hippuric acid 75-85% in 6 hours.

The medicinal product according to the invention may be prescribed as a continuous treatment or else occasionally, for example, in the event of a severe infection without alteration of the patient's condition and/or physiological parameters, either orally with or without a dose. loading or infusion in a few minutes to a few hours according to a dosage of the drug according to the invention (infusion rate will be adapted), it will be indicated that the doses to be administered are variable according to the duration of the treatment, the frequency of the intakes, the host, nature and severity of disease. There may be mentioned a unit dose ranging from about 0.0001 to about 6000 mg, for example an intravenous infusion of about 0.0004% in 10 hours with the exception of its presence at low concentrations as a bacteriostatic preservative in the formulations drugs at doses of less than 20 mg/ml maximum.

The present invention also relates to: the use of: Benzyl alcohol represented by the formula (C? H ₈ O), as an active or bioactive principle after transformation of its precursors, its derivatives or its mixtures have as an active principle benzyl alcohol such as: alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor benzoic acid, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid; pharmaceutically acceptable for the manufacture of a medicinal composition in a form which can be administered intravenously, orally or cutaneously, for the treatment and prevention of the current Covid-19 pandemic and subsequent epidemics or pandemics, the treatment of viral infections or by other common pathogens such as influenza, HIV, hepatitis B and C, Ebola, Zika... as well as other tumoral, inflammatory and hematological pathologies except for its presence in low concentrations as a bacteriostatic preservative in medicinal formulations with doses of less than 20 mg/ml maximum.

Finally, the subject of the invention is a process for the preparation of a medicinal composition intended for the treatment and prevention of the current Covid-19 pandemic and subsequent epidemics or pandemics, the treatment of viral infections or other common pathogenic agents such as flu, HIV, hepatitis B and C, Ebola, Zika, etc. as well as other tumoral, inflammatory and hematological pathologies characterized by the fact that at least one compound chosen from alcohol is dissolved in a physiological solution benzyl represented by the formula ( C? H ₈ O), and its precursors or mixtures have as an active ingredient benzyl alcohol such as: benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor of benzoic acid, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate , benzyl benzoate, benzyl sulphate, S-benzyl glutathione and pharmaceutically acceptable benzyl mercapturic acid, and that the solution thus obtained is placed in a form which can be administered intravenously, orally or cutaneously except for its presence a low concentrations as a bacteriostatic preservative in medicinal formulations at doses of less than 20 mg/ml maximum.

Demonstration of the action of benzyl alcohol represented by the formula ( C ₇ H ₈ O), and its precursors or mixtures have benzyl alcohol as an active ingredient such as: benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor of benzoic acid, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate , benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid.

STATE OF THE PRIOR ART

We know that since December 31, 2019, a new zoonosis has been spreading and cases are increasing around the world to become a pandemic involving a new coronavirus (SARS-CoV-2). This new virus is associated with a mortality of 2%, which is probably overestimated given the uncertainties concerning the denominator. However, multiple clusters of transmission have been identified.

It should be noted that the pediatric forms are rare and that mortality mainly affects elderly patients.

The present invention aims to put an end to the current global crisis covid-19 and to provide an effective and rapid treatment against SARS-CoV-2 as well as other pathologies,

The covid-19 pandemic has turned the world upside down and all states in the world have been affected economically and socially.

All treatments and preventive means are +/- ineffective.

Health services are exhausted.

Several countries have lost control of the spread. Medical treatments do not exist and existing antiviral molecules on the market have been tested ineffective against SARS-CoV-2; currently there are only symptomatic treatments.

There is an intense race to find a vaccine; while the short time to find this famous vaccine and to test it as well as the multitude of transmission clusters calls into question their effectiveness.

The purpose of this study is to provide clinicians with a new therapeutic alternative for simple, rapid and effective management of patients with suspected or confirmed SARS-CoV-2 infection and subsequent epidemics or pandemics, the treatment of viral infections or by other common pathogens such as flu, HIV, hepatitis B and C, Ebola, Zika... as well as other tumoral, inflammatory and hematological pathologies.

PURPOSE OF THE INVENTION

In these circumstances our solution is simple and practical: our invention will make it possible to put an end to this crisis and a return to normal life in the shortest possible time by transforming this incurable pathology into a simple flu-like state that can be quickly managed in a few hours with a clear clinical and biological improvement of patients.

Given the current kinetics of the pandemic, the data provided in this study are likely to evolve and the main sources of information will be recalled throughout the original text of the study.

The advantages of this therapeutic alternative:

• Raw material available and fairly easy production.

• It saves the time of clinical trials on animals and humans: since it is a very old and well-known molecule.

• The risks are minimal since it is a molecule known in the hospital environment and used in daily medical practice as a bacteriostatic preservative in several drug formulations at very low doses. • It is not expensive, available, allows an immediate and synchronized start of treatment for a rapid elimination of the virus as well as a return to normal social life and a liberation of the economy.

• Its rapid and effective mechanisms of action will help prevent the disease from progressing to aggravation.

• It has few side effects and usually are temporary effects.

• Can be administered in the advanced stages of the disease (severe forms) by reducing the doses according to hepatic and renal clearances and vital functions.

• Short duration of treatment which allows a short duration of hospitalization and frees up health services quickly.

• Also, it allows to treat confirmed and suspected cases (contacts +) quickly

• Breaking of the chain of transmission of the virus in a short time and in a synchronous manner.

• Less expensive than vaccines and safer

STATEMENTS OF FIGURES

Fig N=° I: Diagram Of The Product LEILMRE BENCHCOVIR 200 ml

The following description Fig N=° I, allows a schematic representation by way of non-limiting examples,

Fig N=° I:

EXAMPLES OF FORMULATIONS:

Example n=° 1

1 - Glass bottle, graduated for intravenous infusion of 200 ml

2- Benzyl alcohol. 200mg

Distilled water . 200ml

3- Graduation from 10 ml to 200 ml

4- Information label

5- Stainless metal membrane

Example n=° 2

1 - Glass bottle, graduated for intravenous infusion of 200 ml

2- Alpha-acetoxytoluene. 200mg

Glucose. 12.5g

Distilled water . 200ml

3- Graduation from 10 ml to 200 ml 4- Information label

5- Stainless metal membrane

PRESENTATION OF THE ESSENCE (THE SUBSTANCE) OF THE INVENTION

The subject of the present invention is: a new use in medical practice by the intravenous, oral or cutaneous route: Benzyl alcohol represented by the formula (C? H ₈ O), as active principle or bioactive after transformation of its precursors, its derivatives or mixtures thereof have benzyl alcohol as an active ingredient such as: alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4, 5-tetrahydroxycyclohexanoic (quinic acid) a precursor to benzoic acid, toluene, deuteriobenzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl acid mercapturic; pharmaceutically acceptable:

This new application aims to treat infectious, tumoral, inflammatory and hematological pathologies.

The new use is possible, effective and promising since:

• Benzyl alcohol is already present in several intravenous drug formulations at a low concentration as a preservative,

• An ADI (acceptable daily intake) of 5mg/kg/d is authorized by the FAO/WHO committee as food flavoring for benzyl alcohol and alpha-acetoxytoluene or benzyl acetate,

• The new routes of administration allow a direct action of the drug on the pathogenic agents and on the organism with well-known mechanisms of action,

• The intravenous route allows simple, effective and rapid treatment, which reduces the duration of hospitalization and healing, thus breaking the chain of transmission (therefore also a preventive role).

• It also makes it possible to treat confirmed and suspected cases (contacts + or -) quickly, which obviously leads to slowing down the transmission of the virus in a short time and in a synchronous manner. • By its mechanisms of action; Benzyl alcohol appears to boost immune function, allowing the host organism to fight off the virus more effectively. It also suppresses inflammatory processes.

• The toxicity of the treatment and these beneficial and/or undesirable effects are well known since it is a very old molecule, and this will save the time necessary for clinical trials on animals and humans,

• Is inexpensive and helps keep health care costs low

• It also allows an immediate and synchronous start of treatment for a rapid elimination of the virus as well as a return to normal social life and a liberation of the economy.

• The rapid and effective mechanisms of action will prevent the progression of the disease towards aggravation.

• Few side effects and are transient.

EXAMPLES OF FORMULATIONS:

Example n=° 1

1 . Glass bottle, graduated for intravenous infusion of 200 ml

2. Benzyl alcohol. 200mg

Distilled water . 200ml

3. Graduation from 10ml to 200ml

Example n=° 2

1 . Glass bottle, graduated for intravenous infusion of 200 ml

2. Alpha-acetoxytoluene. 200mg

Glucose. 12.5g

Distilled water . 200ml

Cutaneous application

Benzyl acetate patches (32% solution in acetone) MODE FOR CARRYING OUT THE INVENTION

The present invention relating to a new use in medical practice by intravenous or oral route: Benzyl alcohol represented by the formula (C7 H ₈ O), and its precursors or mixtures have as an active ingredient benzyl alcohol such as: Alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor of benzoic acid, toluene , deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid; pharmaceutically acceptable and obtained by a chemical reaction such as the oxidation of benzyl alcohol by an oxidant or other reaction capable of generating benzyl alcohol or its derivatives as the active principle: EXAMPLES OF REALIZATION:

Example n=° 1 (Fig: I)

1 . Glass bottle, graduated for intravenous infusion of 200 ml

2. Benzyl alcohol. 200mg

Distilled water . 200ml

3. Graduation from 10ml to 200ml

4. Information label

5. Stainless metal membrane

Example n=° 2 (Fig: I)

1 . Glass bottle, graduated for intravenous infusion of 200 ml

2. Alpha-acetoxytoluene. 200mg

Glucose. 12.5g

Distilled water . 200ml

3. Graduation from 10ml to 200ml

4. Information label

5. Stainless metal membrane

To keep the stability and homogeneity of the finished product during storage; the formulations should be stored in the dark, ie. each vial in its packaging.

Example n=°3

Cutaneous application.

Benzyl acetate patches (32% solution in acetone) MANNER IN WHICH THE INVENTION IS APPLICABLE

The present invention relates to a new use in medical practice by intravenous or oral route: Benzyl alcohol represented by the formula ( Cy Hs O), and its precursors or mixtures have as an active principle benzyl alcohol such as : Alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor of benzoic acid, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid; pharmaceutically acceptable and obtained by a chemical reaction such as the oxidation of benzyl alcohol by an oxidant or other reaction capable of generating benzyl alcohol or its derivatives as active ingredient: The invention also relates to the possibilities of:

Medicines have benzyl alcohol as the active or bioactive principle after metabolism in the host organism, its derivatives, its precursors, by direct or slow indirect injectable intravenous route for infusions;

Possibly the oral route by syrups, tablets, capsules, or other routes such as the cutaneous route such as patches by way of non-limiting examples.

MODE FOR CARRYING OUT THE INVENTION

The following examples are given to illustrate the present invention:

Example n=° 1

1 . Glass bottle, graduated for intravenous infusion of 200 ml

2. Benzyl alcohol. 200mg

Distilled water . 200ml

3. Graduation from 10ml to 200ml

4. Information label

5. Stainless metal membrane

Example n=° 2

1 . Glass bottle, graduated for intravenous infusion of 200 ml

2. Alpha-acetoxytoluene. 200mg

Glucose. 12.5g Distilled water . 200ml

3. Graduation from 10ml to 200ml

4. Information label

5. Stainless metal membrane To keep the stability and homogeneity of the finished product during storage; the formulations should be stored in the dark, ie. each vial in its packaging.

Example n=°3

Cutaneous application. Benzyl acetate patches (32% solution in acetone)

Claims

CLAIMS - The present invention relates to a medicinal composition for the treatment and prevention of the new Covid-19 pandemic and other infections by other susceptible pathogens, especially viral, as well as other conditions such as tumors, inflammatory and hematological pathologies, alcohol benzyl alcohol and its precursors or mixtures have as active or bioactive ingredient benzyl alcohol such as: alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1, 3, 4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor of benzoic acid, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and the benzyl mercapturic acid; are presented in a new galenic form and applied according to new routes of administration with the exception of the presence of benzyl alcohol at low concentrations as a bacteriostatic preservative (excipients) in medicinal formulations at doses of less than 20 mg /ml max. - A new application in medical practice for therapeutic and/or preventive purposes, intravenously or orally or cutaneously: Benzyl alcohol represented by the formula (C ₇ H ₈ O), and its precursors or mixtures have as an active ingredient or bioactive benzyl alcohol. - A new application in medical practice for therapeutic and/or preventive purposes, intravenously or orally or cutaneously: Alpha-acetoxytoluene or benzyl acetate, and its precursors or mixtures have as an active ingredient or bioactive benzyl alcohol. - A new application in medical practice for therapeutic and/or preventive purposes, intravenously or orally or cutaneously: Benzyl alcohol represented by the formula (C ₇ H ₈ O), and its precursors or mixtures have as an active ingredient or bioactive benzyl alcohol such as: Alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (acid quinic) a precursor of benzoic acid, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid; pharmaceutically acceptable and obtained by a chemical reaction such as the oxidation of benzyl alcohol by an oxidant or other reaction capable of generating benzyl alcohol or its benzyl derivatives as active or bioactive principle.

5- Medicinal composition containing one or more compounds or mixtures characterized in that its administration in the body generates a benzyl group such as benzyl alcohol and / or alpha-acetoxytoluene where benzyl acetate as active or bioactive principle .

6- Composition according to claim 1, containing one or more compounds or mixtures, characterized in that its administration in the body generates a benzyl group such as benzyl alcohol and / or alpha-acetoxytoluene where benzyl acetate as active and/or bioactive principle, and that it is presented in a form which can be administered intravenously, orally or cutaneously such as ointments, gels or patches, with the exception of the presence of benzyl alcohol has weak concentrations as a bacteriostatic or anesthetic preservative as (excipients) in drug formulations at doses less than 20 mg/ml maximum.

7- Composition according to claim 2, containing one or more compounds or mixtures, characterized in that its administration into the body generates benzyl alcohol as active and / or bioactive principle, and that it is in a form administered intravenously, orally or cutaneously as ointments, gels or patches, except for the presence of benzyl alcohol at low concentrations as a bacteriostatic or anesthetic preservative such as (excipients) in drug formulations at doses less than 20 mg/ml maximum.

8- Composition according to claim 3, containing one or more compounds or mixtures, characterized in that its administration in the body generates alpha-acetoxytoluene or benzyl acetate as active and / or bioactive principle, and that it comes in a form that can be administered parenterally, orally or cutaneously, such as ointments, gels or patches.

9- Medicinal composition according to one of claims 1, 2, 3, 4 characterized in that it is in the form that can be administered and consists of the active principle dissolved in a physiological solution buffered at neutral pH or close to neutrality . 10- Medicinal composition according to claim 1, characterized in that it is in the form that can be administered and consists of the active ingredient dissolved in a physiological solution buffered at neutral pH or close to neutral.

11 - Medicinal composition according to claim 2, characterized in that it is in the form that can be administered and consists of the active ingredient benzyl alcohol dissolved in a physiological solution buffered at neutral pH or close to neutrality.

12- Medicinal composition according to claim 3, characterized in that it is in the form that can be administered and consists of the active principle alpha-acetoxytoluene or benzyl acetate dissolved in a physiological solution buffered at neutral pH or close to the neutrality.

13- Medicinal composition according to claim 4, characterized in that it is in the form that can be administered and consists of the active ingredient dissolved in a physiological solution buffered at neutral pH or close to neutral.

14- Composition according to any one of the preceding claims 1, 2, 3, 4, 5 having benzyl alcohol and / or alpha-acetoxytoluene or benzyl acetate, as active or bioactive metabolite, or precursors or mixtures are used for curative and/or preventive therapy.

15- Composition according to claim 1, having benzyl alcohol and / or alpha-acetoxytoluene or benzyl acetate, as active or bioactive metabolite or precursors or mixtures, are used for curative and / or preventive therapy.

16- Composition according to claim 2, having benzyl alcohol, as active or bioactive metabolite or the precursors or mixtures are used for curative and / or preventive therapy.

17- Composition according to claim 3, having alpha-acetoxytoluene or benzyl acetate as active or bioactive metabolite or the precursors or the mixtures are used for curative and / or preventive therapeutic purposes.

18- Composition according to claims 1, 2, 3, 4, 5, 6 containing benzyl alcohol or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for parenteral or oral route of between approximately 0.0001 % and about 10% (w/v). 19- Also; The compositions according to claims 1, 2, 3, 4, 5, 6 containing benzyl alcohol or its precursors or its mixtures with concentrations of the active principle in this solution or mixture for parenteral or oral route of between approximately 0.001% and approximately 15% (w/v).

20- Composition according to claims 1, 2, 3, 4, 5, 6 containing benzyl alcohol or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for parenteral or oral route of between approximately 0.01 % and about 20% (w/v).

21 - Composition according to claim 1, containing benzyl alcohol or its precursors or its mixtures with concentrations of the active principle in this solution or mixture for parenteral intravenous or oral route of between approximately 0.0001% and approximately 10% (w/ v).

22- Composition according to claim 2, containing benzyl alcohol or its precursors or its mixtures with concentrations of the active principle in this solution or mixture for parenteral intravenous or oral route of between approximately 0.0001% and approximately 10% (w/ v).

23- Composition according to claim 4, containing benzyl alcohol or its precursors or its mixtures with concentrations of the active principle in this solution or mixture for parenteral intravenous or oral route of between approximately 0.0001% and approximately 10% (w/ v).

24- Composition according to claim 1, containing alpha-acetoxytoluene or benzyl acetate, or its precursors or mixtures thereof with concentrations of the active ingredient in this solution or mixture for parenteral or oral route of between approximately 0.0001% and approximately 10% (w/v).

25- Composition according to claim 3, containing alpha-acetoxytoluene or benzyl acetate, or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for parenteral or oral route of between approximately 0.0001% and approximately 10% (w/v).

26- Composition according to claims 4, containing alpha-acetoxytoluene or benzyl acetate, or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for parenteral or oral route of between approximately 0.0001% and approximately 10% (w/v).

27- Composition according to claims 4, containing alpha-acetoxytoluene or benzyl acetate, or its precursors or its mixtures with concentrations of the active ingredient in this solution or mixture for parenteral or oral route between approximately 0.001% and approximately 15% (w/v).

28- Composition according to claims 4, containing alpha-acetoxytoluene or benzyl acetate, or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for parenteral or oral route of between approximately 0.01% and approximately 20% (w/v).

29- Composition according to claims 1, 2, 3, 4, 5, 6 containing benzyl alcohol or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for the dermal route of between approximately 0.0001% and approximately 100% (w/v).

30- Composition according to claims 1, 2, 3, 4, 5, 6 containing benzyl alcohol or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for the dermal route of between about 0.001% and about 100 % (w/v).

31 - Composition according to claims 1, 2, 3, 4, 5, 6 containing benzyl alcohol or its precursors or mixtures thereof with concentrations of the active ingredient in this solution or mixture for the dermal route of between approximately 0.01% and approximately 100% (w/v).

32- Composition according to claim 2, containing benzyl alcohol or its precursors or its mixtures with concentrations of the active principle in this solution or mixture for the dermal route of between approximately 0.0001% and approximately 100% (w/v).

33- Composition according to claim 4, containing benzyl alcohol, or its precursors or mixtures thereof, with concentrations of the active principle in this solution or mixture for the dermal route of between approximately 0.0001% and approximately 100% (w/v ).

34- Composition according to claims 1, 3, 4, 5, 6 containing alpha-acetoxytoluene or benzyl acetate, or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for the dermal route of between approximately 0 .0001% and about 100% (w/v).

35- Composition according to claims 1, 3, 4, 5, 6 containing alpha-acetoxytoluene or benzyl acetate, or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for the dermal route of between approximately 0.001 % and about 100% (w/v). 36- Composition according to claims 1, 3, 4, 5, 6 containing alpha-acetoxytoluene or benzyl acetate, or its precursors or mixtures thereof with concentrations of the active principle in this solution or mixture for the dermal route of between approximately 0 .01% and about 100% (w/v).

37- Composition according to claim 3, containing alpha-acetoxytoluene or benzyl acetate, or its precursors or its mixtures with concentrations of the active principle in this solution or mixture for the cutaneous route of between about 0.0001% and about 100% (w/v).

38- Composition according to claim 1, containing benzyl alcohol or its precursors or its mixtures with a concentration of 0.0001 mg/ml to 6000 mg/ml for parenteral routes and infusions; and from 0.001 mg/kg/d to 6000 mg/kg/d for oral or cutaneous forms such as ointments, gels or patches, except for the presence of benzyl alcohol at low concentrations as a bacteriostatic preservative (excipients) in medicinal formulations at doses of less than 20 mg/ml maximum.

39- Composition according to claim 1, containing benzyl alcohol or its precursors or its mixtures with a concentration of 0.001 mg/ml to 8000 mg/ml for parenteral routes and infusions; and from 0.01 mg/kg/d to 8000 mg/kg/d for oral or cutaneous forms such as ointments, gels or patches, except for the presence of benzyl alcohol at low concentrations such as Bacteriostatic or anesthetic preservative as (excipients) in medicinal formulations at doses of less than 20 mg/ml maximum.

40- Composition according to claim 1, containing benzyl alcohol or its precursors or its mixtures with a concentration of 0.01 mg/ml to 10,000 mg/ml for parenteral routes and infusions; and from 0.1 mg/kg/d to 10,000 mg/kg/d for oral or cutaneous forms such as ointments, gels or patches, except for the presence of benzyl alcohol at low concentrations such as Bacteriostatic or anesthetic preservative as (excipients) in medicinal formulations at doses of less than 20 mg/ml maximum.

41 - Composition according to claim 1, containing benzyl alcohol or its precursors or its mixtures with a concentration of 0.0001 mg/ml to 6000 mg/ml for parenteral routes and infusions; and from 0.001 mg/kg/d to 6000 mg/kg/d for oral or cutaneous forms such as ointments, gels or patches, except for the presence of benzyl alcohol at low concentrations as a bacteriostatic or anesthetic preservative as (excipients) in medicinal formulations at doses of less than 20 mg/ml maximum.

42- Composition according to claim 4, containing benzyl alcohol or its precursors or its mixtures with a concentration of 0.0001 mg/ml to 6000 mg/ml for parenteral routes and infusions; and from 0.001 mg/kg/d to 6000 mg/kg/d for oral or cutaneous forms such as ointments, gels or patches, except for the presence of benzyl alcohol at low concentrations as a bacteriostatic preservative or anesthetic as (excipients) in drug formulations at doses less than 20 mg/ml maximum.

43- Composition according to claim 3, containing benzyl alcohol or its precursors or its mixtures with a concentration of 0.0001 mg/ml to 6000 mg/ml for parenteral routes and infusions; and from 0.001 mg/kg/d to 6000 mg/kg/d for oral or cutaneous forms such as ointments, gels or patches.

44- Composition according to claims 1 to 7 containing benzyl alcohol or its precursors or mixtures thereof with a concentration of 0.0001 mg/ml to 6000 mg/ml for parenteral routes and infusions of 0.001 mg/kg/d to 6000 mg/kg/day for oral or cutaneous forms such as ointments, gels or patches.

45- Medicinal composition according to one of claims 1 to 8 characterized in that it is administered at a rate of 0.0001 to 1000 mg / kg / day.

46- Medicinal composition according to one of claims 1 to 8 characterized in that it is administered at a rate of 0.001 to 3000 mg / kg / day.

47- Medicinal composition according to one of claims 1 to 8 characterized in that it is administered at a rate of 0.01 to 6000 mg / kg / day.

48- Medicinal composition according to one of claims 1 to 8 characterized in that it is administered at a rate of 0.1 to 10,000 mg/kg/day.

49- Composition according to any one of the preceding claims 1, 2, 3, 4, 5 having the therapeutic molecules based on benzyl alcohol or its precursors or its mixtures in any diluent water and / or other such as oils as for example corn oil or propylene glycol (by way of example) are used for therapeutic and/or preventive purposes.

50- Process for the preparation of a medicinal composition intended for the treatment and prevention of the new Covid-19 pandemic and other infections by other sensitive pathogens, especially viral, as well as other conditions such as: flu-like conditions, tumours, inflammatory and hematological pathologies, characterized by the fact that at least one compound chosen from benzyl alcohol is dissolved in a physiological solution, such as: alpha-acetoxytoluene or benzyl acetate, benzaldehyde, benzoic acid (from 14C-benzoic acid), 1,3,4,5-tetrahydroxycyclohexanoic acid (quinic acid) a precursor of benzoic acid, toluene, deuterio-benzoic acid, hydroxybenzoic acid, sodium benzoate, benzyl benzoate, benzyl sulfate, S-benzyl glutathione and benzyl mercapturic acid; pharmaceutically acceptable, and that the solution thus obtained is placed in a form which can be administered by injection, orally or cutaneously, such as ointments, gels or patches such as benzyl acetate patches, for example.

51 - Process according to claim 49, characterized in that a physiological solution is prepared having a concentration of 0.0001 to 10% (w/v) in active principle benzyl alcohol and/or alpha-acetoxytoluene.

52- Composition according to any one of the preceding claims from 1 to 51 the therapeutic molecules based on benzyl alcohol and / or alpha-acetoxytoluene or its precursors or its mixtures is called LEILMRE BENCHCOVIR as an INN (international common name)

53- Chemical composition of the LEILMRE BENCHCOVIR product according to any one of the preceding claims from 1 to 51 the therapeutic molecules based on benzyl alcohol and/or alpha-acetoxytoluene or its precursors or its mixtures are used for curative therapeutic purposes and / or preventive except for the presence of benzyl alcohol at low concentrations as a bacteriostatic or anesthetic preservative as (excipients) in medicinal formulations at doses of less than 20 mg/ml maximum.

54- Composition according to any one of the preceding claims from 1 to 51 the therapeutic molecules based on benzyl alcohol and / or alpha-acetoxytoluene or its precursors or its mixtures allowing the use of other dosage forms which can be administered in the human or animal organism aimed therapeutic and / or preventive except for the presence of benzyl alcohol at low concentrations as a bacteriostatic preservative or anesthetic as (excipients) in drug formulations at doses less than 20 mg/ml maximum.